title: Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies.
abstract: Neuroendocrine tumors (NETs) are relatively uncommon. They typically arise in the gastrointestinal tract and lungs, and their incidence seems to be rising. Most patients have advanced disease at the time of diagnosis and many more will relapse after surgery. There is thus a great need for improvements in therapy for advanced neuroendocrine tumors. This article reviews the current therapy for both pancreatic NETs and non-pancreatic gastrointestinal NETs, and discusses recent advances in NET management with an emphasis on targeted therapy.
authors.affiliation: Mayo Clinic, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA. halfdanarson.thorvardur@mayo.edu.
authors.forename: Thorvardur R
authors.initials: TR
authors.lastname: Halfdanarson
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Strosberg
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D015994:Incidence; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents